share_log

Structure Therapeutics to Participate in Multiple Upcoming Healthcare Investor Conferences

GlobeNewswire ·  Jan 30 13:30

SAN FRANCISCO, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases, today announced that management will participate in multiple upcoming healthcare conferences being held in February and March.

Guggenheim SMID Cap Biotech Conference

Format:Fireside chat and 1x1 meetings
Date/time:Wednesday, February 5 at 10:30 a.m. ET
Location:New York, NY
Webcast link:

Leerink Global Healthcare Conference

Format:Fireside chat and 1x1 meetings
Date/time:Monday, March 10 at 1:00 p.m. ET
Location:Miami, FL
Webcast link:

Jefferies Biotech on the Bay Summit

Format:1x1 meetings
Date:Tuesday, March 11
Location:Miami, FL

The live and archived webcasts of the fireside chats will be accessible from the company's website at and replays will be available for 90 days.

About Structure Therapeutics
Structure Therapeutics is a science-driven clinical-stage biopharmaceutical company focused on discovering and developing innovative oral small molecule treatments for chronic metabolic and cardiopulmonary conditions with significant unmet medical needs. Utilizing its next generation structure-based drug discovery platform, Structure Therapeutics has established a robust GPCR-targeted pipeline, featuring multiple wholly-owned proprietary clinical-stage small molecule compounds designed to surpass the scalability limitations of traditional biologic and peptide therapies and be accessible to more patients around the world. For additional information, please visit .

Investors:
Danielle Keatley
Structure Therapeutics Inc.
ir@structuretx.com

Media:
Dan Budwick
1AB
Dan@1abmedia.com


Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
Comment Comment · Views 351

Recommended

Write a comment